208 related articles for article (PubMed ID: 16625818)
1. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome.
Wang M
Curr Opin Investig Drugs; 2006 Apr; 7(4):319-23. PubMed ID: 16625818
[TBL] [Abstract][Full Text] [Related]
2. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
3. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
Boyle CD; Kowalski TJ
Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
6. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Walker BR; Andrew R
Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
Thieringer R; Hermanowski-Vosatka A
Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):911-24. PubMed ID: 16181035
[TBL] [Abstract][Full Text] [Related]
8. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the discovery of 11beta-HSD1 inhibitors.
Boyle CD
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
[TBL] [Abstract][Full Text] [Related]
10. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
11. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
Hermanowski-Vosatka A; Balkovec JM; Cheng K; Chen HY; Hernandez M; Koo GC; Le Grand CB; Li Z; Metzger JM; Mundt SS; Noonan H; Nunes CN; Olson SH; Pikounis B; Ren N; Robertson N; Schaeffer JM; Shah K; Springer MS; Strack AM; Strowski M; Wu K; Wu T; Xiao J; Zhang BB; Wright SD; Thieringer R
J Exp Med; 2005 Aug; 202(4):517-27. PubMed ID: 16103409
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
Tomlinson JW; Stewart PM
Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
[TBL] [Abstract][Full Text] [Related]
13. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Wake DJ; Walker BR
Mol Cell Endocrinol; 2004 Feb; 215(1-2):45-54. PubMed ID: 15026174
[TBL] [Abstract][Full Text] [Related]
14. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
16. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Morton NM
Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Su X; Vicker N; Trusselle M; Halem H; Culler MD; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):169-73. PubMed ID: 18775471
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid exposure and tissue gene expression of 11beta HSD-1, 11beta HSD-2, and glucocorticoid receptor in a porcine model of differential fetal growth.
McNeil CJ; Nwagwu MO; Finch AM; Page KR; Thain A; McArdle HJ; Ashworth CJ
Reproduction; 2007 Mar; 133(3):653-61. PubMed ID: 17379659
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Gu X; Dragovic J; Koo GC; Koprak SL; LeGrand C; Mundt SS; Shah K; Springer MS; Tan EY; Thieringer R; Hermanowski-Vosatka A; Zokian HJ; Balkovec JM; Waddell ST
Bioorg Med Chem Lett; 2005 Dec; 15(23):5266-9. PubMed ID: 16185866
[TBL] [Abstract][Full Text] [Related]
20. Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Aster SD; Graham DW; Kharbanda D; Patel G; Ponpipom M; Santorelli GM; Szymonifka MJ; Mundt SS; Shah K; Springer MS; Thieringer R; Hermanowski-Vosatka A; Wright SD; Xiao J; Zokian H; Balkovec JM
Bioorg Med Chem Lett; 2008 May; 18(9):2799-804. PubMed ID: 18434143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
